In 1832, Thomas Hodgkin described a case series of enlarged lymph nodes, later to be known as Hodgkin Lymphoma (HL) and approximately 60 years later, Dorothy Reed and Carl Sternberg first characterized the abnormal mononucleated Hodgkin and multinucleated Reed-Sternberg cells (HRSC) that are pathognomonic for this disease (K€ uppers, 2009 ). The cell of origin was identified 150 years after Thomas Hodgkin published his case series. Current classification for HL denotes classical HL (cHL), with 4 morphological sub-types, and nodular lymphocyte predominant HL (NLPHL) (Swerdlow et al, 2008) . The pathology of cHL is peculiar, being a B-cell lymphoma with loss of the B-cell phenotype, and being classified by a predominately by the inflammatory tumour microenvironment.
HL has a stable incidence of 1-3 cases per 100 000 persons with a slight male predominance in wealthier countries for which data exists (Engert & Younes, 2015) . Its bimodal age distribution has been recognized since the 1960s, with peaks in both young adults and the elderly (Engert & Younes, 2015) . HL exhibits a seasonal pattern of incidence with an increased incidence in winter and spring compared to summer and autumn . The current treatment of HL is overwhelmingly successful, with 80-90% of patients being cured irrespective of stage (Borchmann et al, 2016; Sasse et al, 2017) . Elderly patients do not have the same excellent outcomes however, probably due to a combination of a more aggressive disease biology and lesser tolerance for the toxic therapies needed to cure younger patients (Sj€ oberg et al, 2012; Borchmann et al, 2018b) .
Emerging techniques in genomic medicine have significantly advanced our understanding of disease biology. This should lead to better prognostication and more targeted therapies, particularly in high risk patients. The goal of this review is to summarize current literature with respect to the biology of HL. It is not intended to be a systematic review of all publications, rather an overview of disease biology with a focus on avenues that might lead to improved prognostication, targeted treatment and post-therapy monitoring.
et al, 2012) . Propagation of HRSC cell lines and development of animal models also created research challenges. To date, only a few cell lines exist that were cultivated from very advanced, multiply relapsed patients, and this should caution the representativeness of data collected from cell lines for most newly diagnosed HL patients. HRSC are dependent on activating, growth-supporting signals from their deregulated microenvironment. Similarly, animal models used to evaluate novel treatment modalities in the past rely on xenografting HL cell lines into immunodeficient mice and ignore the complex interplay between the malignant tumour cells and their microenvironment . Prior to the availability of microdissection, it was problematic to isolate sufficiently pure tumour-derived DNA from the malignant HRSC or lymphocyte predominant (LP) cells, hampering genomic investigations. Once isolation of malignant cells was possible, clonal immunoglobulin gene rearrangements in HRSC were identified, proving their B-cell origin (K€ uppers et al, 1994; Br€ auninger et al, 2003) . Somatic hypermutation in the rearranged variable (V) region of HRSCs leads to the conclusion that HL is of germinal centre (GC) B-cell origin (Klein et al, 1998; Brune et al, 2008) . Additionally, there is evidence that the HRSC undergoes class-switch recombination (Martin-Subero et al, 2006) . Interestingly, many HRSCs contain mutations that lead to a non-functional V region that functionally 'cripples' the cell, which in normal B-cell development should lead to apoptosis, but in HL additional oncogenic events rescue these preapoptotic cells (Kanzler et al, 1996; Br€ auninger et al, 2003) . There is emerging evidence from gene expression analysis that HRSC may be related to a rare normal CD30+ B-cell population, that has a preserved, functional B-cell receptor (BCR) . This is one peculiarity of the HRSC, which can persist despite its non-functional BCR and evade the usual apoptotic fate similar B cells face.
The HRSC appears to respond to ligands within the microenvironment to constituently activate signalling pathways that promote their survival and proliferation. Central to these processes are the Nuclear factor (NF)-jB and Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathways. The HRSC express multiple receptors which activate NF-jB signalling via the tumour necrosis factor (TNF) receptor family (including CD30 Younes, 2015) . The main mechanism for cytokines signalling in HL is via the JAK/STAT pathway, including phosphorylation and activation of multiple STAT transcription factor,s such as STAT3, STAT5 (STAT5A) and STAT6 in HL (Skinnider et al, 2002; Scheeren et al, 2008) . Signalling via the interleukin 21 receptor (IL21R), demonstrated in HL cell lines, enhances and activates STAT3 and STAT5 transcription (Scheeren et al, 2008) . Interestingly, this study also reports STAT5A and STAT5B activation in normal B cells can induce an HRS-like immunophenotype (a loss of B-cell phenotype). The IL13 receptor at least partly mediates STAT6 expression via an autocrine signalling loop (Skinnider et al, 2002) . Receptor tyrosine kinase (RTK) activation in HL also appears to be ligand-mediated and their expression profile is distinct from normal GC B cells and other B-cell non-Hodgkin lymphomas (Renne et al, 2005) . Sphingosine-1 phosphate (S1P) is a recently described ligand of relevance to HL because of its activation of the phosphatidylinositide 3-kinase (PI3K) pathway, mediated by its receptors (S1PRs 1-5). S1P activation in HL leads to increased expression of basic leucine zipper transcription factor, ATF-like 3 (BATF3) in a feed-forward loop via an elevated S1PR1 expression compared to lowered S1PR2 (Vrzalikova et al, 2018) . BATF3 expression is known to be increased in primary HRSC (Brune et al, 2008; Lollies et al, 2018; Vrzalikova et al, 2018) . However, in another newly described oncogenic feedback loop, BATF3 expression also appears to be induced by STAT3/6 transcription factors (JAK/STAT pathway) and, in turn, regulates lymphomagenesis via MYC activation (Lollies et al, 2018) . Hence the constituent activation of multiple signalling pathways (including NF-jB, JAK/STAT, PIK3) allows for HRSC survival and immune evasion.
The anti-apoptosis armour of HRSC remains an area of investigation. Several mechanisms in addition to JAK/STAT, NF-jB and RTK pathways have been described. HRSC demonstrate resistance to CD95 (FAS)-ligand mediated death (via the CD95 inhibitor cFLIP [CFLAR]) (Re et al, 2001 ). Other anti-apoptotic mediators described in HL include BCLXL (BCL2L1), BIK, XIAP and MDM2 (Chu et al, 1999; Kashkar et al, 2006; Kochert et al, 2011; Tiacci et al, 2012) . Small molecule targets to overcome these anti-apoptotic signals could be important for future studies.
There has been debate about the origin of the pathognomonic, multinucleated phenotype of Reed-Sternberg cells. As HRSC have a mixed phenotype of different haematopoietic cell lineages, with high chromosomal copy number complexity, there was speculation that they are derived from fusion of unrelated cells (e.g. a B cell and a non-B cell). However, HRSC have a maximum of two rearranged immunoglobulin alleles providing evidence against fusions between distinct malignant clones (Ikeda et al, 2010) . A process of re-fusion has been demonstrated to occur between mononucleated (Hodgkin) daughter cells to create multinucleated (Reed-Sternberg) cells after incomplete cytolysis (Rengstl et al, 2013) . Multinucleated Reed-Sternberg cells also have little proliferative capacity (Newcom et al, 1988) and hence the Hodgkin cells are thought to be the main source of tumour clones.
In NLPHL, mutations in the immunoglobulin gene preserves partial BCR function, with only partial loss of the Bcell phenotype and preserved CD20 (MS4A1)/BCL6 expression (Brune et al, 2008) . The immunophenotype in NLPHL is in keeping with antigen-selected GC B-cell origin (Br€ auninger et al, 2003) . Rare cases reporting T-cell origin of have been reported by proving clonal T-cell receptor (TCR) gene rearrangements in the absence of immunoglobulin rearrangement. However, debate exists as to whether these isolated cases represent a true diagnosis of HL or a mimic for this disease (Engert & Younes, 2015) .
The genomic landscape
Cytogenetic analysis of HL is hampered by the paucity of malignant cells, limited metaphases and chromosomal instability. Microdissection of HRSC enables the use of genomic techniques, such as comparative genomic hybridisation (CGH), by providing an enriched population of tumour cells. Multiple chromosomal imbalances in tumour biopsies (Ohshima et al, 1999; Hartmann et al, 2008) and HRSC cell lines (Joos et al, 2003) have been reported. In summary, HRSC harbour tremendous cytogenetic complexity with frequent, reoccurring chromosomal imbalances affecting multiple oncogenic pathways . This can lead to constituent activation of pathways normally only transiently active in B cells (K€ uppers, 2009 ). Common examples include copy number increases in 2p12-16 (REL gene, NF-jB pathway) and 9p24 (JAK2 and CD274/PDCD1LG2 [PD-L1/PD-L2] genes, JAK/STAT pathway). Table I provides a summary of copy number changes in HL and NLPHL. For a discussion of genomic landscape in NLPHL see Data S1.
Chromosomal translocations occur in HRSC less frequently than copy number aberrations. Translocation of the immunoglobulin gene loci is reported in about 20% of HL samples, with partner genes also known to be recurrently mutated in other B-cell malignancies (MYC, BCL6 and REL) identified (Martin-Subero et al, 2006) . In this study, 76% of cHL had at least partial deletions in IGH constant regions, suggesting class switch recombination. This finding supports the previous description of HRSC origin.
Somatic mutations in B2M are reported to be common in Nodular Sclerosis (NS) HL. By whole exome sequencing, the prevalence of B2M mutations was shown to be 70% in NSHL, with loss of b2-microglobulin (B2M) (major histocompatibility complex [MHC] class I) expression correlated with lower stage disease and better overall and progression-free survival in one cohort (Reichel et al, 2015) . TNFAIP3 mutations were also identified in this study at a higher frequency than prior reports (60% in NSHL) (Reichel et al, 2015) . TNFAIP3 encodes an ubiquitin-converting enzyme of the NF-jB pathway, and loss of function mutations was recently linked to lower efficacy of chemotherapy (Yang et al, 2018) . By whole exome sequencing, Tiacci et al (2018) found that over 80% of patient samples carry mutations in the JAK/STAT pathway. In this study, the two most commonly mutated genes identified were STAT6 (32%) and SOCS1 (59%) . Another somatic mutation in a gene with regulatory function on the JAK/STAT pathway, PTPN1, is also described. PTPN1 mutations were identified after whole genome (and whole transcriptome) sequencing of two cases of Primary Mediastinal B-Cell Lymphoma (PMBCL), and due to known similarities in the molecular signatures of PMBCL and cHL, these mutations were further investigated in HL (Gunawardana et al, 2014) . The authors described PTPN1 mutations in 20% of dissected HRSC (from cHL tumours) and in two-thirds of examined HL cell lines (Gunawardana et al, 2014) . The PTPNP1 gene is an inhibitory regulator of the JAK/STAT pathway, and the resulting loss of functional PTPN1-B protein in mutated cases leads Sources: (Ohshima et al, 1999; Franke et al, 2001; Joos et al, 2002; Chui et al, 2003; Hartmann et al, 2008; Steidl et al, 2010b; Reichel et al, 2015; Salipante et al, 2016) . cHL, classical Hodgkin lymphoma; NLPHL, nodular lymphocyte predominant Hodgkin lymphoma. to increased activation of the JAK/STAT pathway with phosphorylation of multiple kinases. Taken together, these studies suggest a pivotal role for the JAK/STAT pathway in the pathogenesis of cHL. Other lower frequency somatic mutations, including GNA13, XPO1 and ITPKB have also been described (Camus et al, 2016; Tiacci et al, 2018) , with further research ongoing. Gene expression has also been examined in cHL. One group published a large cohort of 290 patients using the NanoString platform from formalin-fixed, paraffin-embedded (FFPE) tissue samples (Scott et al, 2013) . Their gene expression data was used to design a predictive model, incorporating survival end-points, and then applied to a validation cohort. NanoString can easily be applied to FFPE tissue, making it an attractive platform for use at diagnosis or relapse. However, external validation of the NanoString platform on an independent cohort is yet to be published. This data will be necessary to judge the clinical usefulness of this platform. Another study identified HL-associated micro-RNA expression patterns that differ from healthy patients and normalize when monitored in extracellular vesicles in patient's plasma after successful treatment (van Eijndhoven et al, 2016) . Hence, this approach could be used to monitor treatment. Similarly, monitoring patients after therapy with a liquid biopsy of cell free DNA (cfDNA) could replace or be an adjunct to interim radiology guidance and/or be used to monitor a patient's response to therapy. One small study identified XPO1 mutations from cfDNA in serial patient samples and detected a residual mutational load in patients who went on to relapse (Camus et al, 2016) . Altogether, this data provides proof of concept that cfDNA samples could be used for minimal residual disease monitoring.
The microenvironment in HL
Lymph node tissue involved by HL contains only very few neoplastic HRSC but abundant non-neoplastic cells. The majority of non-neoplastic cells represent a lymphoma-specific response, creating a highly abundant inflammatory tumour microenvironment. HRSC secrete cytokines to attract inflammatory cells, including IL5, CCL5, CCL17; CCL20, CCL22 and CCL28 (Liu & Shipp, 2017) . These lead to a microenvironment comprised of predominantly T cells (Thelper [Th] and T-regulatory phenotype), as well as macrophages, eosinophils, neutrophils, mast cells, B cells and plasma cells (Liu & Shipp, 2017) and prominent connective tissue components, such as fibroblasts and collagen fibres. Herein we discuss the microenvironment features relevant to cHL, however a description of the tumour microenvironment in NLPHL is provided in Data S1.
The composition of the tumour microenvironment in cHL is not entirely unique and certain components may be observed in other entities, such as T-cell lymphoma, and other B-cell lymphomas, such as sclerosis in follicular lymphoma and mediastinal large B-cell lymphoma. However, it is the extent of the non-malignant compartment within the tumour microenvironment that is an outstanding feature of HL. The non-malignant cells recruited into the HL microenvironment also secrete chemokines/cytokines promoting HRSC proliferation and survival Aldinucci et al, 2016 ). An example of this interaction is the secretion of IL3 by T cells recruited into the microenvironment, leading to eosinophil upregulation of the ligands for CD40 and CD30, both of which promote HRSC growth and proliferation (Pinto et al, 1997) . Fibrosis is thought to be mediated by HRSC expression of IL13 and transforming growth factor-b (TGF-b, TGFB1 (Ohshima et al, 2001) . One of the most abundant, highly cHL-specific cytokines in the microenvironment of cHL is CCL17, also known as thymus-and activation-regulated chemokine (TARC). Its relative specificity for cHL has led to its investigation as a disease burden and disease response biomarker (Sauer et al, 2013) . Other examples of feedback mechanisms within the microenvironment have recently been reviewed elsewhere Aldinucci et al, 2016) .
HRSC produce immunosuppressive cytokines (e.g. IL10, TGF-b, Galectin-1) that can regulate and inhibit CD8+ (cytotoxic) T-cell populations and facilitate immune escape by T-cell exhaustion (Liu & Shipp, 2017) . Additionally, HRSC can down-regulate MHC class I or II molecules on their surface via loss of function mutations (e.g. B2M) or translocations (e.g. CIITA) (Steidl et al, 2011a; Reichel et al, 2015) . This can make them 'invisible' to T-cells, but potentially vulnerable to natural killer (NK) cell-mediated toxicity. Therefore, additional immune escape mechanisms might be important. HRSC can express human leucocyte antigen (HLA)-G, HLA-E or MHC class I chain-related protein A (MIC-A) that protect them from NK cells and T-cell cytotoxicity (Engert & Younes, 2015) . HRSC also express CD95 ligand, which induces apoptosis of activated Th1 and CD8+ T-cells (Poppema et al, 1998) . Histologically, HRSC are often surrounded by a rosette of T cells. This morphological feature may function as a source of survival, promoting T cells (mostly Th2 cells) but also form a physical barrier against activated CD8+ cytotoxic T cells. Hence, the microenvironment appears to be a maligned assembly of immunological cells that build a protective and supportive surrounding for HRSC rather than contributing to an active anti-lymphoma response. See Fig 1 for a schematic overview of interactions within the HRSC microenvironment.
The composition of this tumour microenvironment displays striking intra-and inter-tumoural heterogeneity. Assessing these features has become a focus of research with regard to prognostic information and potential therapeutic targets. Associations between the cellular infiltrate and prognosis have been studied using immunohistochemistry (IHC) and gene expression profiling (Steidl et al, 2010a (Steidl et al, , 2011b . Figure 2 illustrates the characteristic immune populations within the microenvironment, by IHC. Here, we will look in more detail into their role and summarize the most important prognostic findings for T cells, B cells and macrophages as participants in the microenvironment.
T cells and NK cells
In the majority of cHL subtypes, T cells are the most abundant cell population in the microenvironment, including Tregulatory cells (T-regs), T helper cells (Th1, Th2) and cytotoxic T-lymphocytes (Wein & K€ uppers, 2016) . CD4+ T cells have a supportive effect on HRSC by both directly shielding and inhibiting them from cytotoxic T lymphocytes (CTLs) and NK(T) cells. Interestingly, human immunodeficiency virus (HIV)-infected patients have an up to 10-fold higher risk of developing cHL, similar or, in some cases, lower compared to their additional risk of developing other lymphomas. However, in contrast to other lymphomas, incidence of cHL might even increase in HIV-infected patients after successful highly active antiretroviral therapy (HAART). This is in stark contrast to the incidence of other lymphomas, for which the risk declines with HAART. These observations are consistent with the supportive role of CD4+ T-cells in cHL pathogenesis after an initial malignant transformation (e.g. Epstein-Barr virus [EBV]-infection) has taken place.
The polarization of Th1 and Th2 cells within the microenvironment is subject to conflicting reports. The Th1 transcription factor, T-bet (TBX21), is detectable in the microenvironment T cells of both cHL and NLPHL by IHC. In one study, the Th2 transcription factor c-MAF (MAF) and T-reg transcription factor FOXP3 were shown by IHC to be expressed at much higher densities in the tumour microenvironment than T-bet (Schreck et al, 2009) . Interestingly, in this study, low numbers of T-regs and Th2 infiltrating T cells were associated with inferior survival. In a more recent report, tissue microarray IHC was applied to a large cohort of cHL samples and Th1 T-bet expression was demonstrated to be more abundant than Th2-associated c-MAF/GATA3 expression (Greaves et al, 2013a) . We consider this an open question as to the association between Th1 and Th2 populations in the immune response to the malignant HRSC cell. The explanation for this discrepancy may relate to T-regs within the microenvironment and their immunosuppressive potential, limiting the activation of different effector T-cell populations (Ishida et al, 2006 ). An increase in T-regs has been shown to be a favourable bio-marker in cHL Greaves et al, 2013b) , although, some controversary exists (Hollander et al, 2018) . However, the mechanism of this effect is unclear, as T-regs can inhibit the humoral immune responses mediated via Th2 cells and have immunosuppressive activity on cytotoxic lymphocytes. The ratio of T helper cells (CD4+) and T effector cells (CD8+) may also correlate with prognosis in cHL, although reports are not consistent. High CD8+ and low CD4+ T-cells were associated with a favourable outcome in one study (AlonsoAlvarez et al, 2017) . In a larger cohort, low CD8+ T cells in early stage disease showed poorer outcomes (AlvaroNaranjo et al, 2005) . In this study, an elevated number of CTLs (by expression of TIA1 and granzyme B) was also correlated with shortened survival. The negative prognostic effect of high numbers of CTLs has been confirmed in other studies Vari et al, 2018) . A recent study reported increased CD56-bright, CD16-dim NK cells with high PD-1 (also termed PDCD1) expression in pre-treatment blood samples from patients with cHL, a finding that reverts to normal after chemotherapy (Vari et al, 2018) . In an in vitro model, the same study showed that monocytes with a tumour-associated macrophage phenotype suppress the activation of NK cells, a feature that was partly reversed by use of an anti-PD-1 antibody (Vari et al, 2018) . The findings have several implications: firstly, CD56-bright NK cells are likely to be players in the immune evasion of cHL due to less potent cytotoxicity and altered cytokine production (IFN-c, IL-10) (Poli et al, 2009 ) as compared to CD56-dim, CD16-bright NK cells from normal controls; secondly, this study identifies an interaction between monocyte/macrophages and NK cells via their respective PD-L1 and PD-1 expression, and thirdly because NK cells might play, at least in part, a role in the sensitivity of cHL to anti-PD-1 therapy (Vari et al, 2018) . Detailed immunophenotyping of T cells and NK cells within the microenvironment may provide further prognostic information. Here, novel technologies, such as multiplex IHC, single-cell transcriptomics and mass cytometry, might be useful.
B cells
B-cell abundance in cHL is associated with a favourable prognosis. The topology of B cells is relevant, as one group demonstrated only non-follicular arranged CD20+ B-cells confer an advantageous prognosis (Greaves et al, 2013b) . Other groups observed improved survival in patients with high numbers of aggregated (lymph follicles) or dispersed Bcells (Panico et al, 2015) . The mechanism of this observation remains uncertain. Anti-tumour activity of Bcells has been proposed, however such B-cell populations could also reflect remnants of pre-existing lymph nodes. Consequently, the high number of B cells might just be a proxy for a less aggressive disease biology causing less destruction of the physiological lymph node architecture. In clinical trials, anti-CD20 antibodies for B-cell depletion initially showed favourable results (Younes et al, 2003) , but this was not confirmed in larger trials (Borchmann et al, 2018a) , a finding that may be consistent with the protective association of B-cell abundance.
Macrophages
Tumour-associated CD68+ macrophages (TAM) can be identified by gene expression profiling (Steidl et al, 2010a) or IHC and are a predictor of overall survival. High TAM content in tumour biopsies was associated with inferior survival in several studies (Touati et al, 2015; Gotti et al, 2017) . A meta-analysis of almost 3000 patients found that high density of TAM (identified by CD68+ or CD163+ expression) was a robust predictor of adverse outcomes in adults (Guo et al, 2016) . However, several negative studies, demonstrating no association with elevated TAM have also been published. Macrophages can be quantified by IHC (CD68 and/or CD163) using manual visual inspection (and quantified by counting cells per high powered field), or digital image analysis. Methodological discrepancies between studies is noted; such as the target of the antibody used (CD68 or CD163), the antibody clone or the method of quantification (Klein et al, 2014) . Heterogeneity in the reporting means that clinical application is not straight-forward, and no guidelines exist for translation of this research outside of clinical trials.
The mechanism of this association between macrophages and aggressive disease biology is not well understood. However, an association between TAM and B cells has been observed. A favourable risk group can be identified by high CD20+ (B cell) background populations and low TAM content (Panico et al, 2015) . The reverse combination of low CD20+/high TAM was significantly associated with lower overall survival in multivariate analysis (Panico et al, 2015) . An association between TAM and NK cells has also been reported (Vari et al, 2018) to be related to their PD-L1 and PD-1 expression, respectively (see Section on T cells and NK cells). Further studies are required to establish a suitable method for macrophage quantification in routine clinical use.
Histopathological characteristics, subtypes and diagnosis
HL is classified into two major subgroups: cHL (95% of patients) and NLPHL (5% of patients) (Swerdlow et al, 2008) . The diagnostic characteristics of NLPHL is described in Data S1. In cHL, HRSC are identified as large cells with a slightly basophilic cytoplasm and multiple large, rounded nuclei with usually one prominent eosinophilic nucleolus. Reed-Sternberg cells must have at least two nucleoli in two separated nuclear lobes to be diagnostic (Swerdlow et al, 2008) . The smaller mononuclear variant morphologies include Hodgkin cells (with similar cytological features), lacunar cells (with more abundant clear/slightly acidophilic cytoplasm that is sensitive to fixation) and mummified cells (with condensed dark chromatin and dark cytoplasm) (Swerdlow et al, 2008) .
The subtyping of cHL is primarily based on features of the microenvironment (Fig 3) . In a simplified view, the dominant or characteristic feature of the microenvironment determines the histology subtype (Nodular Sclerosis -abundant connective tissue; Lymphocyte Rich -abundant B cells; Mixed Cellularity -T cells and macrophages; Lymphocyte Depleted -lack of B cells and T cells). We have provided a more detailed description of the histopathological subtypes of cHL in Data S1.
The malignant phenotype
HRSC have a characteristic immunophenotype co-expressing CD30 and CD15, although 20-30% of cases will be CD15 negative (Engert & Younes, 2015) . They have lost the typical B-cell phenotype. It is currently not known if this is just a side effect of other events in the process of HL tumorigenesis or if this phenotype is selected for to evade the apoptosis a regular B cell would undergo had it incurred non-functional immunoglobulin mutations. HRSC do not express surface BCR and rarely express GC B-cell markers (e.g. BCL6, AID [AICDA]) or surface B-cell proteins (e.g. CD20, CD37, CD53, CD79a) (Swerdlow et al, 2008) . Younes, 2015) . B-cell lineage can be detected by weak nuclear staining of the B-cell activator protein PAX5 on a background of small B cells. HRSC can express markers typically of T cells (e.g. CD3) and cytotoxic lymphocytes (granzyme B). Interestingly, many molecules involved in antigen presentation and the interaction with T cells, such as CD40, CD80 and CD86 are also expressed in HRSCs (Engert & Younes, 2015) . See Data S1 for a description of the malignant phenotype of NLPHL.
EBV signalling
EBV infection occurs in up to 40% of HL in western countries (K€ uppers et al, 2012) . The presence of clonal HRSC with EBV infection (i.e. all the HRSC are derived from a single virus-infected B cell) suggests that EBV may be an early event in disease pathogenesis (Engert & Younes, 2015) . The same EBV viral strain has also been shown to persist at disease relapse, providing further evidence for the crucial pathogenetic relevance of EBV in these cases. EBV association with HRSC is usually demonstrated by either IHC staining for latent membrane protein 1 (LMP1) or EBV-encoded small RNA (EBER) in situ hybridisation. Despite the important role of EBV infection in HL pathogenesis, the EBV-association of a patient's HL currently does not affect treatment algorithms.
Latent EBV infection may be a factor in preventing the HRSC from undergoing apoptosis after crippling somatic hypermutation occurs, leading to immune evasion. Hence, latent EBV infection may be crucial to the survival of HRSC (K€ uppers et al, 2012) . LMP1 mimics constituently active CD40 on B cells and is linked to NF-jB activation in GC cells and to transcriptional reprogramming (Engert & Younes, 2015) . Several studies have demonstrated that latent membrane protein 2A (LMP2A) allows for survival of non-functional B cells within the GC (Portis et al, 2003; Anderson & Longnecker, 2009 ). The LMP2A protein appears to be a functional mimic for the BCR (Engert & Younes, 2015) and its expression in B cells creates a gene expression profile similar to HL cell lines (Portis et al, 2003) . LMP2A expression is also linked to constituent activation of the NOTCH1 pathway (Anderson & Longnecker, 2009 ), although downregulation of many BCR signalling molecules suggests the pathogenesis of HL is probably more complex and multifactorial.
Preliminary data exists that translates this research to clinical practice. The use of autologous, manufactured, EBV-specific (LMP1/2) expanded CTLs has demonstrated efficacy in high-risk and multiply relapsed EBV+ lymphomas (Bollard et al, 2014) . Their results showed a 50% complete response rate for patients with active EBV+ lymphoma (HL and nonHodgkin lymphoma) with minimal toxicity. This study builds on an earlier report (by the same group) of EBV-specific T cells as potentially effective in EBV+ HL. A potential advantage of virus-specific T cells over other cellular immunotherapies is to avoid the need for lymphodepletion (as in many chimeric antigen receptor T [CAR-T] cell protocols) and obviates the risk of cytokine release syndrome (which is not reported with virus-specific T cells).
EBV-associated microRNAs remain an area of investigation as specific signatures are thought to inhibit B-cell apoptosis (Klinke et al, 2014) . In addition, gene expression profiling suggests that EBV may only have a small influence on the transcription profile of HRSC (Tiacci et al, 2012) . In young adults EBV status does not appear to affect prognosis. However, in patients aged over 50 years, inferior outcomes are observed. This may relate to differences in disease biology and other host factors also contributing to the bi-modal incidence of this disease.
Biology-driven treatment in cHL
Antibody directed therapy; antibodies, conjugates, bispecific antigen therapies and chimeric antigen receptors (Borchmann et al, 2003) . However, the translation to clinical trials has been disappointing. SGN-30, a chimeric aCD30-Ab, was tested in a small phase 2 dose escalation study for relapsed/refractory CD30+ lymphoma (Forero-Torres et al, 2009 ). There were no responders in the HL arm, hence trials have not progressed for HL.
Immunotoxin conjugates linked to aCD30-Ab provide direct drug delivery to HRSC. Preliminary trials of aCD30-immunotoxin constructs were hampered by low clinical response rates and major toxicity as well as the emergence of neutralizing antibodies. A humanised aCD30-Ab (5F11) was trialled in a phase 1/2 study but complete results remain unpublished and the interim response rate was limited (Renner & Stenner, 2018) .
Brentuximab vedotin (BV) is an aCD30-Ab conjugated to the microtubule-disrupting agent, monomethyl auristatin E. BV incorporates the chimeric aCD30-Ab SGN-30 into a novel compound (Renner & Stenner, 2018) . The pivotal phase 2 study showed an overall response rate of 75% in relapsed/refractory HL patients (Younes et al, 2012a) . Application of BV in clinical practice now extends to post-transplant consolidation for high risk HL (AETHERA trial) (Moskowitz et al, 2015) and is thought by some investigators to have a role in upfront treatment for advanced stage disease (ECHELON-1) (Connors et al, 2018) . The clinical benefit of upfront BV supplementing doxorubicin, vinblastine and dacarbazine (BV-AVD) compared to other, highly effective, conventional treatment regimens, such as the combination of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone and procarbazine (BEACOPP) is an open question and a direct comparison is yet to be completed. However indirect comparison suggests that BV-AVD is less effective than a positron emission tomography-guided BEACOPP treatment (Borchmann et al, 2018a) . The excellent efficacy of BV is leading to many concurrent new trials that incorporate its' use earlier in contemporary treatment algorithms. A bispecific aCD30-Ab/CD16A construct (AFM13) has also been trialled in a phase 1 study (Rothe et al, 2015) . This compound recruits NK cells to the HRSC for targeted killing. In this dose escalation study, modest activity in relapsed/refractory patients was observed, despite heavy pre-treatment (Rothe et al, 2015) . Preliminary data from a phase 1b study combining AFM13 with pembrolizumab was recently reported, suggesting combination therapy will be tolerable to patients (Ansell et al, 2017) . The use of AFM13, a bi-specific antigen therapy, is an exciting translation from other malignancies but further studies are needed.
Another antibody target within the microenvironment is CD123 [IL3RA], a component of the IL3 receptor with moderate expression on HRSC. It is rarely expressed in other B-or T-cell lymphomas and has limited expression in the normal lymph node. CD123 is present on myeloidderived suppressor cells (MDSC) and correlates with CD68+ TAM that exist within the HL microenvironment (Ruella et al, 2017) . Targeting CD123 has been tested using anti-CD123 CAR-T cells in a murine model of HL (Ruella et al, 2017) . CAR-T cell therapy is a promising avenue for therapy in HL because the cells represent a newly sensitized immune compartment, primed to overcome HRSC immune 'evasion'. There are several clinical trials currently examining aCD30 CAR-T cell therapy in relapsed/refractory HL and results are awaited (RELY-30: NCT02917083; CART30: NCT02259556; ICAR30 T-cells: NCT03383965; ATL-CAR.CD30 cells: NCT03602157; Anti-CD30-CAR T-cells: NCT03049449).
Immunomodulation
Lenalidomide, an immunomodulatory agent, has been trialled in a phase 2 study of relapsed refractory HL (Fehniger et al, 2011) . The grade 3/4 haematological toxicity rate was almost 50% (predominately neutropenia) with overall response rate less than 20%, but one-third of patients achieved complete/partial response or stable disease. Further trials were proposed as combination therapy, however other agents have become available in the interim that demonstrate higher efficacy making this approach less attractive.
JAK/STAT pathway inhibition
Amplification of the 9p24 locus in HRSC provides biological plausibility for JAK/STAT pathway inhibition to be effective. A phase 1 study of SB1518 (an oral JAK2 kinase inhibitor) showed some response in relapsed HL (Younes et al, 2012b) . However, a phase 2 study of ruxolitinib in relapsed/refractory HL showed an overall response rate <10% and adverse events occurred in >40% of patients (all grades) with anaemia, lymphopenia and infection being the most common grade 3/4 adverse events (Van Den Neste et al, 2018) . Interestingly, this study reported patients having an improvement in B-symptoms and pruritis despite progressive disease. Based on this study, JAK-STAT pathway inhibition is unlikely to be clinically useful as a monotherapy but might play a role in combination regimens.
Checkpoint inhibition
A phase 1 study of nivolumab (a PD-1 blocking antibody) showed response rates of >70% in heavily pre-treated HL (Ansell et al, 2015) with drug-related immune-mediated toxicity reported in a quarter of patients. Phase 2 trials of nivolumab in relapsed/refractory HL have continued to show high response rates (~70-80%) with a tolerable and manageable side effect profile (Younes et al, 2016; Maruyama et al, 2017) . Nivolumab has also been successfully applied in postallogeneic transplant patients at relapse (Herbaux et al, 2017) . Pembrolizumab is an alternative anti-PD-1 antibody with good efficacy in phase 1 and 2 trials in heavily pre-treated patients Chen et al, 2017 ). The response rates are similar to that observed with nivolumab (~70%), with a similarly acceptable side effect profile. Both agents are likely to be equivalent in their efficacy and safety. The success of PD-1 inhibitors has prompted further trials incorporating these agents earlier in treatment algorithms.
The mechanism for such high efficacy of checkpoint inhibition is not entirely clear. Although many cases of HL have increased copy numbers of the 9p24 loci detected, and there is some association between the copy number or PD-L1 expression in IHC and outcome to immune checkpoint inhibition, this relationship is not clear enough to base treatment decisions upon. One biomarker recently reported as prognostic for HL patients treated with checkpoint inhibition is the eosinophil count in peripheral blood. Higher counts are associated with improved responses and longer remissions (Hude et al, 2018) . High levels of CD274 expression by HRSC leads to continuous stimulation of the PD-1 receptor on T cells, inhibiting their anti-tumor activity . There is evidence to support re-sensitizing an exhausted Th1 effector population as the mechanism of PD-1 antibody effectiveness, but further studies are needed (Cader et al, 2018) . Furthermore, it is still unclear how the microenvironment of HL changes when patients are treated with immune checkpoint inhibition. More studies examining 
Conclusions
The progress in genomic medicine has given us new insights into the biology of HL. The complex signalling between malignant HRSC/LP cells and the microenvironment defines new biomarkers and therapy targets. We predict progress in molecular monitoring of disease response to be a useful adjunct to standard radiology post-therapy.
As immune escape is one the key features of HL disease pathogenesis, further recognition of mechanisms of immune evasion will lead to new avenues for therapeutic targeting. Logical targets for treatment would 're-programme' the cellular (non-malignant) infiltrate within affected lymph nodes to overcome its anergy and limit its support for HL growth. The application of immunotherapy treatments, such as antibody-targeted therapy and checkpoint inhibition, have improved outcomes for high risk and multiply relapsed patients. Furthermore, a major clinical challenge in contemporary HL treatment is the fact that many patients are overtreated due to a lack of early, high-sensitive disease response biomarkers. Advances in the molecular understanding of HL coupled with the emergence of highly sensitive genomic technologies could form the basis of new minimal residual disease monitoring technologies that could help to prevent overtreatment of patients that are cured quickly and therefore prevent treatment-related morbidity and improve patients' long-term outcomes. 
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Data S1. The Translational Science of Hodgkin Lymphoma; a focus on diagnosis, disease subtyping and the specific entity of Nodular Lymphocyte Predominant Hodgkin Lymphoma.
